HighTower Advisors
INKT icon

HighTower Advisors’s MiNK Therapeutics INKT Stock Holding History

HighTower Advisors’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,068
Closed -$35.3K – 3894
2024
Q4 		$35.3K Sell
5,068
-105
-2% -$714 ﹤0.01% 3491
2024
Q3 		$36K Buy
5,173
+104
+2% +$882 ﹤0.01% 3452
2024
Q2 		$43K Sell
5,069
-19
-0.4% -$185 ﹤0.01% 3325
2024
Q1 		$43K Sell
5,088
-6
-0.1% -$56 ﹤0.01% 3272
2023
Q4 		$49K Buy
5,094
+3,453
+210% +$36K ﹤0.01% 3306
2023
Q3 		$13K Sell
1,641
-57
-3% -$928 ﹤0.01% 3367
2023
Q2 		$30K Buy
1,698
+658
+63% +$13.2K ﹤0.01% 3218
2023
Q1 		$18K Hold
1,040
– – ﹤0.01% 3155
2022
Q4 		$27K Hold
1,040
– – ﹤0.01% 3100
2022
Q3 		$22K Buy
+1,040
New +$20.5K ﹤0.01% 2965

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
C
Covestor London, United Kingdom $144M AUM 37.32% 1-Year Est. Return

HighTower Advisors's INKT Position: Q1 2025 in Review

HighTower Advisors sold out of MiNK Therapeutics (INKT) in Q1 2025, closing a stake of 5,068 shares — an estimated $35.3K sold.

HighTower Advisors first reported a position in INKT in Q3 2022 and held it in 10 quarters. The position peaked at $49K in Q4 2023. 17 funds tracked by Wall St. Rank hold INKT as of Q1 2025.

  • HighTower Advisors reported no remaining MiNK Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HighTower Advisors sold 5,068 MiNK Therapeutics shares in Q1 2025, an estimated $35.3K.
  • HighTower Advisors first reported a position in MiNK Therapeutics in Q3 2022 and held it in 10 quarters.
  • HighTower Advisors's MiNK Therapeutics position peaked at $49K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q1 2025.

Based on HighTower Advisors's 13F filing for Q1 2025, filed 13 May 2025.